Affymax, Inc. (AFFY) said it may sell up to $60 million of its registered common stock to Azimuth Opportunity, Ltd. under an issuer managed equity facility.
Paul Cleveland, executive vice president and chief financial officer of Affymax said the equity facility provides prudent financing flexibility as the company begins preparation for potential commercial launch of Hematide in the renal anemia market.
For comments and feedback: editorial@rttnews.com